Fernando R Moya
Overview
Explore the profile of Fernando R Moya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moya F, Mazela J, Shore P, Simonson S, Segal R, Simmons P, et al.
BMC Pediatr
. 2019 May;
19(1):147.
PMID: 31078143
Background: Current guidelines for management of respiratory distress syndrome (RDS) recommend continuous positive airway pressure (CPAP) as the primary mode of respiratory support even in the most premature neonates, reserving...
2.
Lista G, Maturana A, Moya F
Eur J Pediatr
. 2017 Aug;
176(10):1287-1293.
PMID: 28795220
Conclusions: given the current status of neonatal care, it seems that lung injury and BPD could be reduced with multiple strategies starting early in the delivery room. Literature underlines the...
3.
Guardia C, Moya F, Sinha S, Simmons P, Segal R, Greenspan J
J Pediatr Pharmacol Ther
. 2012 Dec;
17(3):220-7.
PMID: 23258964
Objectives: Reintubation and subsequent mechanical ventilation (MV) in preterm infants after surfactant replacement therapy are associated with excess morbidity and mortality and likely increase in-hospital costs. Specific surfactant therapy selection...
4.
Thomas N, Guardia C, Moya F, Cheifetz I, Markovitz B, Cruces P, et al.
Pediatr Crit Care Med
. 2012 Jul;
13(6):646-53.
PMID: 22791092
Objective: Inhibition of surfactant function and abnormal surfactant synthesis lead to surfactant dysfunction in children with acute hypoxemic respiratory failure. We evaluated whether intratracheal lucinactant, a synthetic, peptide-containing surfactant, was...
5.
Logan J, Moya F
Ther Clin Risk Manag
. 2009 May;
5(1):251-60.
PMID: 19436610
Introduction: Available literature suggests that the advantage of animal-derived surfactants over first-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results...
6.
Parikh N, Lasky R, Kennedy K, Moya F, Hochhauser L, Romo S, et al.
Pediatrics
. 2007 Feb;
119(2):265-72.
PMID: 17272615
Objective: Our goal was to relate postnatal dexamethasone therapy in extremely low birth weight infants (birth weight of < or = 1000 g) to their total and regional brain volumes,...
7.
Khattak A, Padhye N, Williams A, Lasky R, Moya F, Verklan M
Early Hum Dev
. 2006 Sep;
83(6):361-6.
PMID: 16978804
Background: Maturation of the autonomic nervous system has not been studied in high-risk very low birth weight (VLBW) infants in the first few weeks of life. Aim: To characterize developmental...
8.
Moya F, Sinha S, DAgostino R
Pediatrics
. 2006 Jan;
117(1):245-7.
PMID: 16396889
No abstract available.
9.
Moya F, Lally K
Semin Perinatol
. 2005 Jul;
29(2):112-7.
PMID: 16050529
The mortality rate associated with congenital diaphragmatic hernia (CDH) varies widely between centers and remains relatively high despite widespread use of new therapeutic modalities. Many of these have been implemented...
10.
Phokela S, Peleg S, Moya F, Alcorn J
Am J Physiol Lung Cell Mol Physiol
. 2005 Jun;
289(4):L617-26.
PMID: 15951333
1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] has been reported to stimulate lung maturity, alveolar type II cell differentiation, and pulmonary surfactant synthesis in rat lung. We hypothesized that 1,25(OH)(2)D(3) stimulates expression of surfactant...